跳至主要内容
临床试验/NCT06921551
NCT06921551已完成不适用

Exploratory Pilot Study on the Prolonged Use of the ABLE Exoskeleton in Multiple Sclerosis

ABLE Human Motion S.L.1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2025年4月7日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
19
试验地点
1
主要终点
Number of therapeutic objectives achieved

研究概览

简要总结

The goal of this study is to explore the potential clinical benefits of the ABLE Exoskeleton as part of a rehabilitation program in people with multiple sclerosis. The main question it aims to answer is:

Can a rehabiliation program with the ABLE Exoskeleton help to mantain the physical and psychosocial health of people with multiple sclerosis?

Participants will:

  • Have a gait training session of 60 min with the exoskeleton once a week for 12 months at the clinic
  • Have an evaluation (tests and questionnaires) every 3 months at the clinic

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •18 to 70 years old
  • •Diagnosed with multiple sclerosis
  • •Currently undergoing outpatient physical therapy treatment at the investigation site
  • •Ability to give informed consent

排除标准

  • •Significant osteoporosis that may increase the risk of fracture
  • •Unresolved fractures in the pelvis or extremities, or history of fragility fractures in the lower extremities in the last 2 years
  • •Spinal instability (or spinal orthoses, unless authorized by a physician)
  • •Severe spasticity: Level 4 on the Modified Ashworth Scale
  • •Orthostatic hypotension. Inability to tolerate a minimum of 30 minutes standing
  • •Uncontrolled autonomic dysreflexia
  • •Medical instability
  • •Unstable cardiovascular system (CVS), hemodynamic instability, untreated hypertension (SBP>140, DBP>90 mmHg), unresolved deep venous thrombosis (DVT)
  • •Serious comorbidities, including any condition that a physician deems inappropriate for use of the ABLE Exoskeleton or to complete participation in the study
  • •Skin integrity problems on the contact surfaces of the device or that would prevent sitting
  • •Grade I or higher on EPUAP (European Pressure Ulcer Advisory Panel, 2019) on areas that will be in contact with the exoskeleton
  • •Colostomy
  • •Anthropometric measurements outside the values compatible with ABLE Exoskeleton. In particular, height not between 1.5-1.9 m, or weight over 100 kg
  • •Anatomical constraints (such as eg length differences, users unable to position themselves inside the device) that are incompatible with the device
  • •Restrictions in range of motion that prevent normal gait from being achieved or preventing the completion of a normal transition from sitting to standing or standing to sitting
  • •Heterotopic ossification
  • •Known pregnancy or breastfeeding
  • •Cognitive impairment that results in the inability to follow simple instructions, particularly psychological or cognitive problems that do not allow a participant to follow study procedures

研究组 & 干预措施

Intervention with exoskeleton

Experimental

Participants will undergo 60-min gait training sessions with the exoskeleton as part of their rehabilitation program once a week for up to 12 months

干预措施: ABLE Exoskeleton (Device)

结局指标

主要结局

Number of therapeutic objectives achieved

时间窗: From baseline to the end of the training program at 12 months

Two therapeutic objectives per participant will be defined at baseline. At the end of the training program, it will be assessed if the objectives were accomplished or not.

Location and level of pain

时间窗: Baseline, 3, 6, and 12 months post-training

The location and level of pain using the numeric rating scale (NRS) will be assessed at baseline, every 3 months and at the end of the gait training program to assess the reduction of pain aftr the training

Lower extremity muscle strenght

时间窗: Baseline, 3, 6, and 12 months post-training

The Daniels Muscle Testing scale will be used to measure the strength of muscles in the lower extremities at baseline, every 3 months and at the end of the gait training program to assess motor function after the training. Scores range from 0 (absence of muscle activity) to 5 (normal muscle activity)

Modified Ashworth Scale (MAS)

时间窗: Baseline, 3, 6, and 12 months post-training

The Modified Ashworth Scale (MAS) measures spasticity in patients with lesions to the central nervous system. The scale assigns a grade of spasticity from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension). It will be evaluated at baseline, every 3 months and at the end of the gait training program without the device to assess the change in the spasticity after training

Timed 25-Feet Walk test (T25FW)

时间窗: Baseline, 3, 6, and 12 months post-training

The Timed 25-Foot Walk (T25FW) test measures the time a person needs to walk 25 feet. This test will be assessed at baseline, every 3 months, and at the end of the gait training program without the device to assess the change in the walking function after the training

6-Minute Walk Test (6MWT)

时间窗: Baseline, 3, 6, and 12 months post-training

The 6-Minute Walk Test (6MWT) measures the distance a person can walk in 6 minutes. This test will be assessed at baseline, every 3 months, and at the end of the gait training program without the device to assess the change in the walking function after the training

Borg Rating of Perceived Exertion

时间窗: Baseline, 3, 6, and 12 months post-training

The Borg Rating of Perceived Exertion (RPE) scale is used to measure a person's perception of their effort and exertion, breathlessness, and fatigue during physical activity. Scores range from 6 (no exertion at all) to 20 (maximal exertion). It will be evaluated during the 6MWT at baseline, every 3 months, and after the end of the gait training program without the device to assess the change in the perceived exertion after the training

Trunk Impairment Scale (TIS)

时间窗: Baseline, 3, 6, and 12 months post-training

The Trunk Impairment Scale (TIS) measures the motor impairment of the trunk through the evaluation of static and dynamic sitting balance as well as coordination of trunk movement. The total score ranges from 0 (minimal performance) to 23 (perfect performance). This test will be assessed at baseline, every 3 months, and at the end of the gait training program without the device to assess the change in the trunk impairment after training

Barthel Index (BI) score

时间窗: Baseline, 3, 6, and 12 months post-training

The Barthel Index (BI) will be used to assess the participants' ability to perform mobility and self-care activities of daily living (ADL). The total score ranges from 0 (total dependency) to 100 (independency). It will be evaluated at baseline, every 3 months, and after the gait training program without the device to assess the change in the independence to perform ADL after the training

Modified Fatigue Impact Scale (MFIS) score

时间窗: Baseline, 3, 6, and 12 months post-training

The Modified Fatigue Impact Scale (MFIS) provides an assessment of the effects of fatigue in terms of physical, cognitive, and psychosocial functioning in persons with multiple sclerosis. The total score ranges from 0 to 84, with higher scores meaning a higher impact of fatigue. It will be evaluated iat baseline, every 3 months and at the end of the gait training program without the device to assess the change in the fatigue after the training

Multiple Sclerosis Quality of Life-54 (MSQoL-54) scores

时间窗: Baseline, 3, 6, and 12 months post-training

The Multiple Sclerosis Quality of Life-54 (MSQoL-54) is a multidimensional health-related quality of life (QoL) measure that combines both generic and MS-specific items into a single instrument. There is no single overall score for the MSQoL-54. Two summary scores - physical health and mental health - can be derived from a weighted combination of scale scores. The higher the score, the best the outcome. It will be evaluated at baseline, every 3 months and at the end of the gait training program without the device to assess the change in the QoL after the training

Self-perceived impact on general health status

时间窗: 3, 6, and 12 months post-training

Participants' perceptions of the impact on their general health will be evaluated by the completion of a self-report questionnaire on the perceived impact on general health. This questionnaire has been designed by the researchers and intends to identify to what extent participants feel that the ABLE Exoskeleton contributed to a change in their health. The questionnaire covers 7 categories (cardiovascular system, musculoskeletal pain, neuropathic pain, bladder and bowel, spasticity, and sleep quality) using a 7-point Likert scale to assess the change.

Level of motivation

时间窗: After 12 months post-training

Participants' perceptions on the level of motivation generated by the program with the ABLE Exoskeleton will be evaluated by the completion of a self-report questionnaire using a 7-point Likert scale. This questionnaire has been designed by the researchers.

Psychosocial Impact of Assistive Devices Scale (PIADS) score

时间窗: After 12 months post-training

The Psychosocial Impact of Assistive Devices Scale (PIADS) is a 26-item, self-reported questionnaire that provides a measure of user perception and other psychological factors associated with assistive technology devices. Scores range from -78 (maximum negative impact) to +78 (maximum positive impact). It will be used to assess the effects of the ABLE Exoskeleton on functional independence, well-being, and quality of life of participants after the training program experience

Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) score

时间窗: After 12 months post-training

The Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) is a 12-item outcome measure that assesses user satisfaction with two components (Device and Services) using a 5-point scale ranging from 1 (not satisfied) to 5 (very satisfied). Only the 8 items referred to the device will be evaluated from participants and the whole 12 items from the therapists to measure user satisfaction with the ABLE Exoskeleton after the training program experience

次要结局

  • Number of steps walked(At session 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10)
  • Distance walked(At session 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10)
  • Time spent upright and time spent walking(At session 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
不适用
Study to evaluate the effect of continuous use of the test product on muscle mass and body fatHealthy adults
JPRN-UMIN000041388imeQ RD inc.40
进行中(未招募)
不适用
sing GPS trackers in dementia patients to improve quality of lifeQuality of life of people diagnosed with dementia or memory impairment who are at risk of wandering or getting lostMental and Behavioural DisordersUnspecified dementia
ISRCTN16242918South West Yorkshire Partnership NHS Foundation Trust45
已完成
不适用
Prospective, controlled pilot study for the use of non-contact perfusion and thermography measurements in patients with peripheral arterial disease, chronic venous insufficiency, or diabetes mellitus (with or without ulceration) compared to patients with spider vein varikosisCirculatory disorders in venous disease, arterial occlusive disease and diabetes mellitus in cf. to spider veins varicosisI87I70.2E13I83.9Other disorders of veinsAtherosclerosis of arteries of extremitiesOther specified diabetes mellitusVaricose veins of lower extremities without ulcer or inflammation
DRKS00013886Phlebologisches Studienzentrum am Venenzentrum der Dermatologischen und Gefäßchirurgischen Kliniken37
尚未招募
不适用
A pilot study of traditional acupuncture as an additional treatment for irritable bowel syndrome-diarrhoeaAlternative and Complementary Medicine - Other alternative and complementary medicineirritable bowel syndromeOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
ACTRN12622000073707ew Zealand College of Chinese Medicine40
招募中
4 期
An observation study on the long-term efficacy of Huisheng oral solution after radical operation of stage II to IIIb non-small cell lung cancer (NSCLC)on-small cell lung cancer(NSCLC)
ITMCTR2100004907Sichuan Provincial People's Hospital